InVivo targets $22B injectable pain-relief market | Regulatory Roundup

InVivo Therapeutics engages the FDA to discuss the regulatory path for its injectable hydrogel for neurological pain, anticipating an annual market potential of $22 billion.

InVivo engages the FDA to move forward on injectable pain-relief hydrogen, aims for $22B yearly market [1]
InVivo Therapeutics [2] (OTC:NVIV [3]) is hoping to break into what may be a $22 billion annual market with its new combination injectable hydrogel for pain management in the lower back, legs, neck or arms.

Late last month, the company submitted a request to meet with the FDA's Office of Combination Products and the Center for Devices & Radiological Health to discuss the path for the product, a hydrogel engineered for sustained release of therapeutic molecules.